News
CELC
--
0.00%
--
Jefferies Initiates Coverage On Celcuity with Buy Rating, Announces Price Target of $48
Jefferies analyst Maury Raycroft initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of $48.
Benzinga · 09/07 11:44
--Jefferies Starts Celcuity at Buy with $48 Price Target
MT Newswires · 09/07 09:40
Do Insiders Own Lots Of Shares In Celcuity Inc. (NASDAQ:CELC)?
Every investor in Celcuity Inc. ( NASDAQ:CELC ) should be aware of the most powerful shareholder groups. Institutions...
Simply Wall St. · 09/02 11:42
Stonepine Capital Management, LLC Buys Amryt Pharma PLC, CTI BioPharma Corp, Chiasma Inc, Sells ...
GuruFocus News · 08/24 15:38
Commodore Capital Lp Buys Celcuity Inc, C4 Therapeutics Inc, Cytokinetics Inc, Sells , Trillium ...
GuruFocus News · 08/23 21:38
Granite Point Capital Management, L.p. Buys Angel Pond Holdings Corp, Cerberus Telecom ...
GuruFocus News · 08/17 19:38
BRIEF-Celcuity Q2 Loss Per Share $1.11
reuters.com · 08/09 21:09
Celcuity Q2 EPS $(0.66) Down From $(0.17) YoY
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.66) per share. This is a 288.24 percent decrease over losses of $(0.17) per share from the same period last year.
Benzinga · 08/09 20:06
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities * After follow-on offering, Celcuity had approximately $94.4 million of cash on hand * Expanded clinical devel...
ACCESSWIRE · 08/09 20:00
-- Earnings Flash (CELC) CELCUITY Reports Q2 Loss $-0.66
MT Newswires · 08/09 16:01
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021/ Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in ...
ACCESSWIRE · 08/05 12:00
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
MINNEAPOLIS, MN / ACCESSWIRE /August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will re...
ACCESSWIRE · 08/02 11:30
Cowen initiates Celcuity with an outperform rating on breast cancer diagnostic
Cowen has initiated shares of Celcuity (CELC +6.2%) with an overweight rating but no price target. The company is developing a companion diagnostic, CELsignia, for breast cancer. CELsignia uses live
Seekingalpha · 07/29 17:28
--Cowen Initiates Coverage on Celcuity With Outperform Rating
MT Newswires · 07/29 07:09
--Needham Starts Celcuity at Buy With $50 Price Target
MT Newswires · 07/27 08:58
Celcuity to Participate in the William Blair Biotech Focus Conference
MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in t...
ACCESSWIRE · 07/08 20:15
Where Do Hedge Funds Stand On Celcuity Inc. (CELC)?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to ...
Insider Monkey · 06/30 13:06
Technology and Healthcare names dominate midday movers
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite...
Seekingalpha · 06/29 16:34
Cerevel Therapeutics, Avinger leads healthcare gainers; DiaMedica Therapeutics, MediWound among major losers
Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifesciences RSLS -24%, Celcuity (CELC)...
Seekingalpha · 06/29 15:00
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.